Recent Posts
- Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase February 13, 2021
- Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia January 25, 2021
- Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis January 25, 2021
- Eyenovia To Report Third Quarter 2020 Results December 16, 2020
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com